Novo Nordisk's blockbuster diabetes drug Ozempic reduced patients' risk of death in a kidney disease study. This latest study shows that the drug is useful in a range of diseases. Scientists said in the “New England Journal of Medicine” on Friday that patients with kidney disease due to diabetes were one-fifth less likely to die if they took Ozempic instead of a placebo during the study.
诺和诺德的Ozempic可降低肾脏疾病患者的死亡风险
Novo Nordisk's Ozempic reduces risk of death in patients with kidney disease
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.